Journal profile · HEMATOLOGY
Expert Review of Hematology
ISSN 1747-4086 · eISSN 1747-4094 · Taylor and Francis Ltd. · ENGLAND · Founded 2008
Expert Review of Hematology: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.95; hybrid open access; median 93 days to acceptance (103 articles, last 24 months); community-reported acceptance: fairly easy; 132 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Expert Review of Hematology is published by Taylor and Francis Ltd. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Lymphoma Diagnosis and Treatment, Acute Myeloid Leukemia Research and Chronic Lymphocytic Leukemia Research, together about 25.7% of its articles. Its main subfields are Hematology and Genetics. (generated from OpenAlex topic counts and CAS ranking data)
Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.
Source: LetPub
Research area (LetPub): HEMATOLOGY
Main research topics OpenAlex counts of recent articles; shares are approximate
- Lymphoma Diagnosis and TreatmentMedicine9.2%
- Acute Myeloid Leukemia ResearchMedicine8.8%
- Chronic Lymphocytic Leukemia ResearchMedicine7.7%
- Hemoglobinopathies and Related DisordersMedicine5.9%
- Platelet Disorders and TreatmentsMedicine5.8%
- Multiple Myeloma Research and TreatmentsMedicine5.8%
- Hemophilia Treatment and ResearchMedicine5.7%
- Myeloproliferative Neoplasms: Diagnosis and TreatmentMedicine5.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
Top journal: noReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.95LetPub ·
- CiteScore 2026-06
- 4.1LetPub ·
- SJR 2026-06
- 0.7LetPub ·
- SNIP 2026-06
- 0.76LetPub ·
- h-index
- 31LetPub ·
- h-index
- 70OpenAlex ·
- i10-index
- 820OpenAlex ·
- 2-year mean citedness
- 2.3OpenAlex ·
- Self-citation rate
- 3.6%LetPub ·
- Share of gold OA articles
- 6.25%LetPub ·
Volume
- Articles per year
- 111LetPub ·
Articles by year OpenAlex count · 1,815 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 95 | 29 | 47 |
| 2025 | 132 | 43 | 220 |
| 2024 | 103 | 35 | 491 |
| 2023 | 115 | 49 | 979 |
| 2022 | 106 | 29 | 1,079 |
| 2021 | 97 | 22 | 1,254 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
93 daysMedian, submission to acceptance · P25–P75 66 days – 136 days
- Acceptance to online
- median 11 days (103 articles)
- Submission to online
- median 108 days
- Sample
- 103 articles with submission and acceptance dates (256 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Taylor and Francis Ltd.
- Country or region
- ENGLAND
- Language
- English
- Founded
- 2008
- ISSN
- 1747-4086
- Electronic ISSN
- 1747-4094
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Expert Review of Hematology
What CAS zone is Expert Review of Hematology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Expert Review of Hematology is in Zone 4 of Medicine, and in Zone 4 of the minor category Hematology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Expert Review of Hematology?
The latest impact factor listed by LetPub is 2.95; CiteScore 4.1, h-index 70.
How long does peer review take at Expert Review of Hematology?
Based on the dates recorded on 103 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 93 days (interquartile range 66–136 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Expert Review of Hematology?
According to LetPub and DOAJ records, Expert Review of Hematology is indexed in SCIE and Scopus.
Is Expert Review of Hematology open access, and what is the APC?
Expert Review of Hematology is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .